Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan

被引：0
|
作者：
Xiuting Mo
Kensuke Moriwaki
Kosuke Morimoto
Kojiro Shimozuma
机构：
[1] Ritsumeikan University,Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology
[2] Kyoto University,Graduate School of Medicine
[3] Ritsumeikan University,Division of Health Services Research, Department of Biomedical Sciences, College of Life Sciences
[4] Ritsumeikan University,Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology
来源：
Clinical Drug Investigation | 2022年 / 42卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 609
页数：10
相关论文
共 50 条
  • [21] Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
    Zaim, Remziye
    Redekop, W. Ken
    Groot, Carin A. Uyl-de
    FRONTIERS IN HEALTH SERVICES, 2023, 3
  • [22] Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Wielage, Ron
    Schwartzberg, Lee
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1404 - 1414
  • [23] Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
    Khan, Iftekhar
    Morris, Stephen
    Hackshaw, Allan
    Lee, Siow-Ming
    BMJ OPEN, 2015, 5 (07):
  • [24] Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK plus advanced non-small-cell lung cancer in France
    Sivignon, Marine
    Monnier, Remi
    Tehard, Bertrand
    Roze, Stephane
    PLOS ONE, 2020, 15 (01):
  • [25] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB PLUS IPILIMUMAB VS. PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF NON-SQUAMOUS, ADVANCED NON-SMALL CELL LUNG CANCER IN THE USA
    Chen, J.
    Velcheti, V.
    Padula, W.
    VALUE IN HEALTH, 2022, 25 (07) : S342 - S342
  • [26] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS
    Klijn, S.
    Van de Wetering, G.
    Malcolm, B.
    Dale, P.
    Pompen, M.
    Stevanovic, J.
    VALUE IN HEALTH, 2018, 21 : S46 - S46
  • [27] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
    Bersanelli, Melissa
    Tiseo, Marcello
    Banna, Giuseppe L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
  • [28] Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
    Lu, Shun
    Yu, Yongfeng
    Fu, Shijun
    Ren, Hongye
    PLOS ONE, 2018, 13 (10):
  • [29] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [30] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST -LINE TREATMENT OF ADVANCED MELANOMA
    Baker, T. M.
    Paly, V. F.
    Sabater, J.
    Okoro, T.
    Kotapati, S.
    Briggs, A.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
12345